Evidence map›Paper›PMID 36166409›Full record

ArticleMolecular pharmaceutics2022

Scanning Analysis of Sequential Semisolvent Vapor Impact To Study Naltrexone Release from Poly(lactide-co-glycolide) Microparticles.

John Garner, Sarah Skidmore, Justin Hadar, Haesun Park, Kinam Park, Andrew Otte, Young Kuk Jhon, Xiaoming Xu, Bin Qin, Yan Wang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. PLGA-based long-acting injectable (LAI) formulations.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  2. In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide).Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

John GarnerAkina, Inc., West Lafayette, Indiana 47906, United States.
Sarah SkidmoreAkina, Inc., West Lafayette, Indiana 47906, United States.
Justin HadarAkina, Inc., West Lafayette, Indiana 47906, United States.
Haesun ParkAkina, Inc., West Lafayette, Indiana 47906, United States.
Kinam ParkAkina, Inc., West Lafayette, Indiana 47906, United States.ORCID 0000-0001-8202-6084
Andrew OtteBiomedical Engineering and Pharmaceutics, Purdue University, West Lafayette, Indiana 47907, United States.
Young Kuk JhonOffice of Pharmaceutical Quality, Office of Lifecycle Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Xiaoming XuOffice of Pharmaceutical Quality, Office of Testing and Research, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States.ORCID 0000-0003-1672-0830
Bin QinOffice of Generic Drugs, Office of Research and Standards, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Yan WangOffice of Generic Drugs, Office of Research and Standards, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Akina (United States) · USCenter for Drug Evaluation and Research · USPurdue University West Lafayette · US

Funding

Injectable naltrexone 2-month depot formulationsUH3DA048774 · NIDA · PURDUE UNIVERSITY · PI PARK, KINAM · 2022 to 2024
$4.9M
Injectable naltrexone 2-month depot formulationsUG3DA048774 · NIDA · PURDUE UNIVERSITY · PI PARK, KINAM · 2019 to 2020
$2.9M
NIDA NIH HHS UG3 DA048774NIDA NIH HHS UH3 DA048774
6 · The paper itself

Abstract

Poly(lactide-co-glycolide) (PLGA)-based microparticle formulations have been a mainstay of long-acting injectable drug delivery applications for decades. Despite a long history of use, tools and techniques to analyze and understand these formulations are still under development. Recently, a new characterization method was introduced known as the surface analysis after sequential semisolvent impact using sequential semisolvent vapors. The vapor-based technique is named, for convenience, surface analysis of (semisolvent) vapor impact (SAVI). In the SAVI method, discretely controlled quantities of selected organic semisolvents in the vapor phase were applied to PLGA microparticles to track particle morphological changes by laser scanning confocal microscopy. Subsequently, the morphological images were analyzed to calculate mean peak height (

Indexed as

NaltrexonePolyglactin 910Calorimetry, Differential ScanningDrug Delivery SystemsMicrospheresParticle SizePolylactic Acid-Polyglycolic Acid CopolymerNaltrexonePolyglactin 910Polylactic Acid-Polyglycolic Acid Copolymerlong-acting depotmicroparticlesPLGAsemisolventsolvent vaporsurface analysis

Identifiers

PMID36166409
PMCPMC9643650
OpenAlexW4297251743

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.